PennyStock Alert
6 years ago
Stryker acquires Arrinex
Source: GlobeNewswire Inc.
Stryker (NYSE:SYK) announced today it has completed the acquisition of Arrinex, Inc., a medical device company headquartered in Menlo Park, California, that has developed ClariFix®, a novel cryoablation technology for the treatment of chronic rhinitis. This condition, which affects over 24 million people in the U.S. each year, may cause runny nose, congestion, sneezing and nasal itching. Arrinex, which was founded in 2013, began commercializing ClariFix in late 2017 in the U.S. ClariFix further expands Strykerβs Ear, Nose and Throat (ENT) portfolio with a unique product to address a large, underpenetrated segment of the ENT market where Stryker does not currently compete.
βThe acquisition of Arrinex is highly complementary to Strykerβs ENT portfolio, which is part of our Neurotechnology business,β said Spencer Stiles, Strykerβs Group President, Neurotechnology, Instruments and Spine. βThis acquisition aligns with our focus on providing ENT physicians with new technologies that deliver more treatment options and better patient outcomes.β
Forward-looking statements
stealthways
8 years ago
think Stryker has been very complacent about emerging tech ,mainly due to its leading strength in the Ortho segment (this is not uncommon in various industries and the skeletons of similarly over confident companies are littered) --- and has failed to see how significant the dangers are of transformational tech. The bashers of the AMDA stock, don't kid yourself, has also affected the Stryker over confidence with their own tech.. "Asleep at the switch" comes to mind....
Lets assume that Stryker, for what ever reason, "wakes up", from its tech hibernation, and see that AMDA is cleaning the books, auditing assets etc, and other hallmarks of a potential sale. Lets further assume, they understand how AMDA tech would likely help Zimmer take many Billions of their revenue away over the next 5 to 10 years and add incremental new revenue, from new sources, to Zimmer..
If you look at Strykers history, it looks to me to have more experience than Zimmer at growing by acquisition ... Even if Stryker has some kind of relationship with Zimmer currently likely this would be superficial. Anyways, based on these assumptions, why would Stryker sit back and let this deal happen with no interference (i.e. competing bid) from it .... even if they know of the personal connections between AMDA and Zimmer. So for example lets says Stryker calculates an AMDA sale to Zimmer would take $5 Billion off the Present Value (roughly equal to market cap) of Stryker.. and lets say Zimmer trys to low ball a $100 million bid for AMDA... Under this scenario, no matter what relationships are, it would make no sense for Stryker to just sit back and let this deal happen with no response. Even if Stryker thinks Zimmer may potentially outbid them , its better for Stryker to have Zimmer pay up at least , if they do succeed.
Bottom line is Stryker needs to wake up to emerging tech and protect their future by trying to own the tech at AMDA....The bashing and manipulation of AMDA hides the true value, and danger if in the hand of a competitor, of the technology..time is of the essence...
stealthways
8 years ago
Lobo needs to act quick ....Stryker has a chance to acquire Amedica and its tech before Zimmer Biomet. If Stryker, drops the ball, and allows Zimmer to get Amedica, with world wide patents for its new SiNi, 3-D printing tech, main asian markets near approval, anti-infective properties, and many more advantages, Zimmer will be a tough night in Hip-knee, and gain share in spine .... It is simple for Stryker to block Zimmer, if they act quick.... Zimmer is preparing now to acquire this tech but Stryker , by using its superior M&A skills can be quicker and block this threat ....